CD4 lymphopenia (CD4 < 200 cell/mm3) is also frequently reported, lasting beyond day 30 (42) and up to 1 year (16) after CD19-directed CAR T-cell therapy and up to 9–12 months after BCMA-directed therapy (26). This evidence concerns the gene CD4 and lymphopenia.